Boehringer Ingelheim‘s Ofev (nintedanib) preserved the lung function of nine idiopathic pulmonary fibrosis patients waiting for a lung transplant, a study reported. The research, “Safety of nintedanib before lung transplant: an Italian case series,” appeared in the journal Respirology Case Reports. A lung transplant is…
An Australian study showed that AD-114, an investigative therapy for idiopathic pulmonary fibrosis (IPF) developed by AdAlta, prevented the infiltration of immune cells and collagen build-up in lung cells from IPF patients. AD-114 also reduced fibrotic injury in a mouse model. The study, “Anti-fibrotic Effects of…
The Pulmonary Fibrosis Foundation’s annual Broadway Belts for PFF! fund-raiser generated a record $350,000 this year. This brought the amount raised in the event’s eight years to nearly $1.2 million. The proceeds support the foundation’s work and research seeking a cure for pulmonary fibrosis. Julie Halston, a Broadway star and comedienne,…
A lung transplant can benefit those whose pulmonary fibrosis (PF) stems from Hermansky-Pudlak syndrome (HPS), a study indicate. The study, “Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation,” was published in the journal PLOS One. HPS is a rare…
Reata Pharmaceuticals’ bardoxolone methyl significantly improved the exercise capacity of patients with idiopathic lung disease (ILD) associated with pulmonary hypertension (PH), a Phase 2 clinical trial showed. The ongoing LARIAT study (NCT02036970) is evaluating the safety and efficacy of bardoxolone in about 165 patients whose PH is associated with…
Researchers identified a small group of genes that may promote idiopathic pulmonary fibrosis (IPF) after analyzing gene expression profiles in fibroblasts isolated from the lungs of patients with the disease. The study, “Global Gene Expression Analysis in an in vitro Fibroblast Model of Idiopathic Pulmonary Fibrosis Reveals Potential Role…
Idiopathic pulmonary fibrosis (IPF) increases a person’s health and economic burden years before it is diagnosed, a multi-year Canadian study shows. The research, “Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada,” appeared in the journal ClinicoEconomics and Outcomes Research. IPF is a progressive…
Real-world data shows that treatment with Ofev (nintedanib, marketed by Boehringer Ingelheim) helps stabilize idiopathic pulmonary fibrosis (IPF) and is well-tolerated, a German study reports. The research, “Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis,” was published in the journal Respiration. Ofev and…
Genetic sequencing and the speed with which it can help diagnose a child’s disease — in addition to revealing the genes that cause at least half of the 7,000 rare diseases currently known — was the focus of a discussion by three top New York geneticists. The Feb. 28 conference,…
IBIO-CFB03, an investigational fibrotic therapy, was selected as iBio’s lead candidate for further development, the company announced in a press release. The product may be a new treatment option for idiopathic pulmonary fibrosis (IPF) and scleroderma. Fibrosis is characterized by inflammation and buildup of collagen…
Get regular updates to your inbox.
